Back

Transthyretin-directed antisense oligonucleotide therapy effects on ATTRv myocardiopathy

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pharmacotherapy 2 Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ana Beatriz Garcia

CHULN and Faculty of medicine of the University of Lisbon, Lisbon (Portugal)

7 More presentations in this session

Presentation thumbnail
Survey and interview-based study on readiness of heart failure polypill implementation
Doctor R. Bin Raja Shariff (Selangor, MY)
Abstract Slides
Presentation thumbnail
Atrioventricular conduction disorders associated to betablocker treatment in patients with heart failure
Doctor D. Marcu (Iasi, RO)
Abstract Slides
Presentation thumbnail
The efficacy of combination therapy of corticosteroids and methotrexate for cardiac sarcoidosis, prolonged analysis
Doctor Y. Nishihata (Tokyo, JP)
Abstract Slides
Presentation thumbnail
Telmisartan versus Enalapril in heart failure with reduced ejection fraction patients with moderately impaired kidney functions; randomized controlled trial. (TRIUMF trial)
Doctor S. Abouel Naga (Cairo, EG)
Abstract Slides
Presentation thumbnail
Meta-analysis on the role of potassium binders in optimization of guideline-directed medical therapy and safety outcomes in patients with heart failure
Doctor I. Tumang (Taguig, PH)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - pharmacotherapy 2

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Presentation
Audience Q&A
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources